Kilitch Healthcare’s eye drops, distributed via Walmart, Target, and CVS, are being recalled due to safety concerns flagged by the FDA. The recall ensued following the FDA’s discovery of unsanitary conditions. This affects eye drops expiring between November 2023 to September 2025. Users face potential eye infections or harm, posing higher risks as ophthalmic drugs bypass natural eye defenses. Despite no reported adverse events, the FDA urges immediate cessation of use and return to the point of purchase. This recall aligns with recent industry incidents, emphasizing the criticality of safety standards in ophthalmic products.
Amidst safety concerns, Kilitch Healthcare India Ltd., based in Mumbai, instigated a recall of various eye drops retailed at major outlets like Walmart, Target, and CVS. The U.S. FDA flagged the recall, prompted by findings of unsanitary conditions during their investigations. All eye drop lots expiring between November 2023 and September 2025 are included in the recall. Users are at risk of potential eye infections or harm due to the sterile nature of these eye products. This highlights the imperative for stringent safety measures in ophthalmic drugs, with the FDA advocating for immediate cessation of use.
Mumbai’s Kilitch Healthcare India Ltd. is undertaking a recall of various eye drops available at Walmart, Target, and CVS due to potential safety concerns, as reported by the U.S Food and Drug Administration (FDA).
The recall was initiated after discovering unsanitary conditions during the agency’s investigation. It encompasses all eye drop lots within expiry, spanning expiration dates from November 2023 to September 2025.
These recalled products were distributed nationwide through wholesalers, retailers, and Velocity Pharma LLC, a product distributor. The impacted lubricant and multi-symptom eye drops were retailed under diverse labels including Walmart, Rugby, Target, Rite Aid, Leader, Velocity, and CVS.
Individuals who have used these affected products are at potential risk of eye infections or related harm. Ophthalmic drug products like these eye drops are meant to be sterile, and their use poses an elevated risk due to their direct application to the eyes, bypassing some of the body’s natural defenses.
Currently, Kilitch Healthcare has not received any reports of adverse events associated with this recall.
The FDA strongly advises consumers to discontinue the use of the recalled eye drops and return them to the place of purchase.
This recall aligns with other recent incidents: Cardinal Health, Inc. recently recalled specific Leader branded eye drops supplied by Velocity Pharma, citing potential risks of eye infections. Additionally, Pharmedica USA LLC, based in Phoenix, recalled Purely Soothing 15 percent MSM eye drops at the consumer level earlier in March due to non-sterility concerns.
In mid-September, the FDA issued warnings to eight companies, including CVS Health and Walgreens Boots Alliance, Inc., cautioning against manufacturing or marketing unapproved ophthalmic drug products, that were deemed violating federal law.
The recall of eye drops distributed through Walmart, Target, and CVS by Kilitch Healthcare unveils critical safety concerns affirmed by the FDA’s findings of unsanitary conditions. The affected eye drops, expiring between November 2023 and September 2025, pose significant risks of eye infections or harm due to their intended sterility. Despite no reported adverse incidents, the FDA emphasizes the urgency for consumers to halt usage and return the products. This incident resonates with recent recalls, underlining the paramount importance of upholding rigorous safety protocols in ophthalmic drug manufacturing for safeguarding consumer health and well-being.
